Clinical trials: Chemotherapy-induced Thrombocytopenia
Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura
A Study of PN20 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are: Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a…
- Trial name
- NCT06523088
- Testing
- PN20
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia.
- Conditions
- Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
- Trial name
- NCT01933035
- Testing
- Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center